Brain metastases reirradiation.

Autor: Petit C; Département d'oncologie-radiothérapie, institut Paoli-Calmettes, Marseille, France., Tallet A; Département d'oncologie-radiothérapie, institut Paoli-Calmettes, Marseille, France; UMR1068, Inserm, Centre de recherche en cancérologie de Marseille (CRCM), Marseille, France. Electronic address: talleta@ipc.unicancer.fr.
Jazyk: angličtina
Zdroj: Cancer radiotherapie : journal de la Societe francaise de radiotherapie oncologique [Cancer Radiother] 2024 Nov; Vol. 28 (6-7), pp. 538-546. Date of Electronic Publication: 2024 Oct 15.
DOI: 10.1016/j.canrad.2024.09.005
Abstrakt: The advances in cancer screening and therapies have allowed the improvement of metastatic patients' survival, including those with brain metastases. This led to a substantial shift in brain metastases patients' management for whom whole-brain radiation therapy, formerly widely used, has given way to a more focused management in which single- or multifractionated stereotactic radiation therapy now plays a predominant role. Although stereotactic radiation therapy offers excellent local control rates (70 to 90%), it does not prevent brain recurrence outside the radiation field, which is all the more frequent the higher the number of initial metastases and the longer the patient's survival. In the case of brain recurrence after irradiation, therapeutic options will depend both on the previous treatment and on the features of the recurrence. This article aims to review the available data on the efficacy and tolerability of various reirradiation schemes in different clinical situations.
(Copyright © 2024. Published by Elsevier Masson SAS.)
Databáze: MEDLINE
Externí odkaz: